Recompensation in Cirrhosis: Rewriting the Natural History

Create Account

Availability

Registration Required

https://aasld.zoom.us/j/84283510987

Apr 28, 2026 12:00 PM - 1:00 PM ET

Cost

$0.00

Credit Offered

No Credit Offered

Description
Learning Objectives
Faculty and Disclosures
Privacy Policy

Recompensation is a new concept in the management of patients with portal hypertension, however there are significant gaps in knowledge. This webinar will address definition of hepatic recompensation, the role of etiological cure or control as a prerequisite for recompensation in viral and non-viral cirrhosis, management strategies, and clinical outcomes after recompensation. This activity is intended for fellows/trainees, gastroenterologists, nurse practitioners and hepatologists.

COPYRIGHT: All faculty in this activity have given their permission for publication ©2026 AASLD.

Upon completion of this activity, participants should be able to:

• Define hepatic recompensation.
• Explain the role of etiological cure or control as a prerequisite for recompensation in viral and non-viral cirrhosis.
• Recognize clinical outcomes and trajectories among patients who achieve recompensation.
• Identify current knowledge gaps in the management of patients who have achieved recompensation.

This educational activity has been planned in accordance with the AASLD Financial Disclosure Policy and ACCME Standards for the Integrity and Independence in Accredited Continuing Education by members of the Continuing Medical Education Committee. As an accredited provider, AASLD must collect information from all planners, faculty and others involved in the planning and control of continuing medical education (CME) activities to disclose all financial relationships with ineligible companies during the prior 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, in ineligible companies. Individuals must disclose financial relationships with ineligible companies regardless of their view of the relevance of the relationship to the content.

The American Association for the Study of Liver Diseases (AASLD) has implemented a system to mitigate conflicts of interest for each CME activity to help ensure content is objective, fair balanced, independent, and free of commercial bias. All relevant conflicts pertaining to this activity have been mitigated.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Anahita Rabiee, MD, MHS

Salvatore Piano, MD, PhD

Elizabeth C. Verna, MD

Rohit Loomba, MD, MHSc

Privacy Policy: https://www.aasld.org/terms-use-and-privacy-policy